Evidence map›Paper›PMID 27250768›Full record

ReviewMicrobiology and molecular biology reviews : MMBR2016

Genetically Engineered Phages: a Review of Advances over the Last Decade.

Diana P Pires, Sara Cleto, Sanna Sillankorva, Joana Azeredo, Timothy K Lu

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microbiology and molecular biology reviews : MMBR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 220 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
220citing papers in PubMed, 2 pooled it
33.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

220 citing papers in PubMed, 2 syntheses or guidelines pooled it, 396 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

160 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Diana P PiresDepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA Centre of Biological Engineering, University of Minho, Braga, Portugal.
Sara CletoDepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID 0000-0003-1273-0142
Sanna SillankorvaCentre of Biological Engineering, University of Minho, Braga, Portugal.
Joana AzeredoCentre of Biological Engineering, University of Minho, Braga, Portugal.
Timothy K LuDepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA timlu@mit.edu.
Massachusetts Institute of Technology · USUniversity of Minho · PT

Funding

MIT Center for Integrative Synthetic BiologyP50GM098792 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WEISS, RON · 2013 to 2017
$11.0M
Mucin Glycans in the Regulation of Microbial VirulenceR01EB017755 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI RIBBECK, KATHARINA · 2013 to 2022
$3.6M
High-Throughput Nanoscale Approaches to Studying and Inhibiting Amyloid ToxicityDP2OD008435 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LU, TIMOTHY · 2011 to 2011
$2.4M
NIBIB NIH HHS R01 EB017755NIGMS NIH HHS P50 GM098792NIH HHS DP2 OD008435
6 · The paper itself

Abstract

Soon after their discovery in the early 20th century, bacteriophages were recognized to have great potential as antimicrobial agents, a potential that has yet to be fully realized. The nascent field of phage therapy was adversely affected by inadequately controlled trials and the discovery of antibiotics. Although the study of phages as anti-infective agents slowed, phages played an important role in the development of molecular biology. In recent years, the increase in multidrug-resistant bacteria has renewed interest in the use of phages as antimicrobial agents. With the wide array of possibilities offered by genetic engineering, these bacterial viruses are being modified to precisely control and detect bacteria and to serve as new sources of antibacterials. In applications that go beyond their antimicrobial activity, phages are also being developed as vehicles for drug delivery and vaccines, as well as for the assembly of new materials. This review highlights advances in techniques used to engineer phages for all of these purposes and discusses existing challenges and opportunities for future work.

Indexed as

BacteriaBacteriophagesCRISPR-Cas SystemsDNA, ViralDrug Delivery SystemsGenetic EngineeringGenome, ViralPhage TherapyDNA, Viral

Identifiers

PMID27250768
PMCPMC4981678
OpenAlexW2409985107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.